In cells, Yale platform links condensates to neurodevelopmental disorders

Images of cultured cells show aberrant biomolecular condensates (green) gathered inside cell nuclei. The Schlieker Laboratory has now built CondenScreen, a platform that links these abnormal clusters to neurodevelopmental disorders and searches for molecules that might stop their buildup.

The platform rests on MLF2, a protein the team identified as a biomarker of pathological condensates. Unlike markers tied to one particular disease, MLF2 appears across dysfunctional condensates, giving researchers a common signal to track. That matters because the same cellular behavior has already been associated with neurodegenerative diseases including frontotemporal degeneration, Parkinson’s disease and Alzheimer’s disease.

Working with the Yale Center for Molecular Discovery, the researchers removed each of 20,000 genes from cultured human cells, one by one, then imaged the cells to see which changes prevented abnormal condensates from forming. Several of the strongest gene candidates were associated with neurodevelopmental disorders, including microcephaly. The result also exposed a striking difference in timing: condensates can accumulate over decades in neurodegenerative disease, while neurodevelopmental conditions emerge within months.

CondenScreen also tested nearly 2,000 small molecules in cell models of DYT1 dystonia, a severe movement disorder often appearing in childhood. Several promising compounds reduced the buildup of pathological condensates, and those compounds are already approved by the U.S. Food and Drug Administration. The researchers are now screening tens of thousands of additional compounds, although it remains unclear whether the condensates drive disease or are bystanders.

So what changes in practice? Researchers gain a shared way to search for disease mechanisms and drug candidates when the proteins involved are difficult to target with traditional pharmacology. Yale’s next step is to study CondenScreen’s gene candidates in brain organoids—tiny, lab-grown three-dimensional models—because a child’s brain cannot be directly examined this way. The evidence is still confined to laboratory models, but the platform is publicly available and gives the field a route from cellular clues toward therapies.